Approval · Notice of Compliance 26752 · 2021
SIMVASTATIN: Notice of Compliance 26752
Issued October 1, 2021
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 26752
- Date
- October 1, 2021
- Company
- Sivem Pharmaceuticals UlcSaint-Laurent, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Abbreviated New Drug Submission (ANDS)
- Submission class
- Other
- Canadian reference product
- ZOCOR (Merck Frosst Canada Inc.)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| SIMVASTATIN | 02386291 | Marketed |
| SIMVASTATIN | 02386305 | Marketed |
| SIMVASTATIN | 02386313 | Marketed |
| SIMVASTATIN | 02386321 | Marketed |
| SIMVASTATIN | 02386348 | Marketed |
Medicinal ingredients
- SIMVASTATIN 5 MG per TAB
- SIMVASTATIN 10 MG per TAB
- SIMVASTATIN 20 MG per TAB
- SIMVASTATIN 40 MG per TAB
- SIMVASTATIN 80 MG per TAB